Phase 2 and Phase 3 trials so far havent reported an excess of serious heart events on retatrutide, but they were short and werent designed to test that question
Courses were required to include evidence of dose escalation (i.e., multiple strengths) to reduce inclusion of very short or incomplete treatment attempts
The most realistic timeline for retatrutide being available in the UK is late 2027 to mid-2028, followed by NHS availability if its recommended by NICE, around 2029
This review examines the biological mechanisms underlying GLP-1 RA therapy in MASLD/MASH, analyzes the mechanistic distinctions between mono-, dual-, and triple agonists, and synthesizes current clinical evidence supporting their utilization in individuals with this condition
The base case, based on the company's prior pattern with tirzepatide, is that filing follows within roughly six months of TRIUMPH-1 topline
Patients must have medical insurance, meet the income criteria, and be prescribed medicine thats part of the Good Days formulary
